AL
EPRS

Airain Ltd’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Airain Ltd’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-12,411
Closed -$71K – 1279
2015
Q2 		$71K Buy
+12,411
New +$84.7K ﹤0.01% 832

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Airain Ltd's EPRS Position: Q3 2015 in Review

Airain Ltd sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2015, closing a stake of 12,411 shares — an estimated $71K sold.

Airain Ltd first reported a position in EPRS in Q2 2015 and held it in 1 quarter. The position peaked at $71K in Q2 2015. 41 funds tracked by Wall St. Rank hold EPRS as of Q3 2015.

  • Airain Ltd reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2015 after selling out during the quarter.
  • Airain Ltd sold 12,411 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2015, an estimated $71K.
  • Airain Ltd first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q2 2015 and held it in 1 quarter.
  • Airain Ltd's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $71K in Q2 2015.
  • 41 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2015.

Based on Airain Ltd's 13F filing for Q3 2015, filed 9 Nov 2015.